MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE: MAIA ) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI) in the ongoing Phase 2 and pivotal Phase 3 clinical trials of its novel telomere-targeting agent ateganosine as a treatment for non-small cell lung cancer (NSCLC). Enrollment is complete for the Part C of Phase 2 trial, THIO-101, which evaluates ateganosine sequenced with the CPI cemiplimab. MAIA recently announced 90.5% interim disease control (DCR) for the combination therapy in the efficacy evaluable population who had at least one tumor scan after starting treatment. Ateganosine’s measures of efficacy are close to triple the reported outcome for standard-of-care treatment with chemotherapy.
Story updates
MAIA Biotechnology, Inc. (NYSE: MAIA ) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI) in the ongoing Phase 2 and pivotal Phase 3 clinical trials of its novel telomere-targeting agent ateganosine as a treatment for non-small cell lung cancer (NSCLC). Enrollment is complete for the Part C of Phase 2 trial, THIO-101, which evaluates ateganosine sequenced with the CPI cemiplimab.
5% interim disease control (DCR) for the combination therapy in the efficacy evaluable population who had at least one tumor scan after starting treatment. Ateganosine’s measures of efficacy are close to triple the reported outcome for standard-of-care treatment with chemotherapy.